{"id":"doi:10.1038/s41698-026-01579-8","kind":"article","title":"Evaluating neoantigen-vaccine responses through mechanistic and model-based frameworks","authors":["Ibrahim EIK","Laurén I","Veerman RE","Jönsson S","Ytterberg AJ","Lindqvist A","Mangsbo SM","Friberg LE"],"author_count":8,"year":2026,"published":"2026-06-24","venue":"NPJ precision oncology","cited_by":0,"doi":"10.1038/s41698-026-01579-8","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.1038/s41698-026-01579-8","archive_url":"https://space-kitty.com/papers/doi:10.1038/s41698-026-01579-8","updated":null,"pmid":"42342810","pmcid":"PMC13294367","openalex_id":null,"pdf_url":"https://europepmc.org/articles/PMC13294367/pdf","abstract":"Therapeutic cancer vaccines activate tumor-specific T-cells to reduce tumor burden, yet face challenges when integrating and translating multi-level complex preclinical data into actionable insights. We present a model-based framework to integrate diverse preclinical data, comparing synthetic long peptide vaccines with or without adjuvant stimuli to a vaccine-drug conjugate approach by Adaptable Drug Affinity Conjugate technology. This technology provides modular and rapid conjugate formation via high-affinity binding between a peptide-tagged vaccine antigen and a CD40-targeting antibody, acting as an adjuvant and delivery vehicle. Our developed semi-mechanistic modelling framework successfully linked dosing to tumor dynamics, incorporating four sub-models: pharmacokinetic, peptide uptake by antigen-presenting cells, T-cell response, and tumor growth in TC-1 and MC38 tumors. Model-based simulations highlighted the importance of affinity conjugation on pharmacokinetics and efficacy. Effector T-cells mediated tumor shrinkage. Antibody dose-dependent effects were identified and quantified in the immune-responsive MC38 model. This framework supports rational vaccine optimization and translational decision-making. The graphical abstract was created in https://BioRender.com .","abstract_license":"CC-BY (article license as recorded by Europe PMC; abstract reproduced unmodified apart from markup removal)","license":"CC-BY","is_open_access":true,"peer_reviewed":null,"categories":[],"details":null,"provenance":"europepmc","attribution":"Abstract of \"Evaluating neoantigen-vaccine responses through mechanistic and model-based frameworks\" by Ibrahim EIK, Laurén I, Veerman RE et al., https://doi.org/10.1038/s41698-026-01579-8, used under its Creative Commons Attribution license (CC-BY); markup removed, otherwise unmodified.","topics":[{"slug":"mrna-cancer-vaccines","name":"mRNA Therapeutics & Cancer Vaccines","domain_slug":"medicine"}],"cited_in_dossiers":[]}